Inozyme Pharma’s (INZY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report published on Wednesday morning,Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright also issued estimates for Inozyme Pharma’s Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.62) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.89) EPS.

Other equities analysts have also issued reports about the stock. Stifel Nicolaus started coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a research report on Tuesday. Jefferies Financial Group reissued a “buy” rating and issued a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.71.

Inozyme Pharma Price Performance

Inozyme Pharma stock traded down $0.08 during mid-day trading on Wednesday, reaching $4.02. 322,995 shares of the company traded hands, compared to its average volume of 270,187. The company has a current ratio of 7.68, a quick ratio of 9.84 and a debt-to-equity ratio of 0.51. The firm’s fifty day moving average is $5.10 and its two-hundred day moving average is $4.92. Inozyme Pharma has a fifty-two week low of $2.71 and a fifty-two week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. Sell-side analysts anticipate that Inozyme Pharma will post -1.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inozyme Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of INZY. Deerfield Management Company L.P. Series C acquired a new stake in Inozyme Pharma during the 2nd quarter valued at $52,000. Meeder Asset Management Inc. bought a new position in shares of Inozyme Pharma in the 2nd quarter valued at about $68,000. Values First Advisors Inc. bought a new stake in Inozyme Pharma during the second quarter worth $76,000. SG Americas Securities LLC acquired a new stake in shares of Inozyme Pharma during the 3rd quarter worth about $81,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Inozyme Pharma in the 2nd quarter valued at $84,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.